Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20764806 | 0.86 | PPARG (0.41) | PPARGPPARARAB9AALDH1A1CYP2A6 | |
| SCHEMBL8018718 | 0.85 | MAOA (0.47) | RAB9AALDH1A1CYP2A6MAOAMAOB | |
| SCHEMBL1314001 | 0.84 | AGXT (0.42) | ALDH1A1MAOBSMN1; SMN2LMNAMAPT | |
| SCHEMBL4616887 | 0.82 | PPARG (0.45) | PPARGPPARAALDH1A1KDM4ELMNA | |
| SCHEMBL4603142 | 0.82 | PPARG (0.45) | PPARGPPARAALDH1A1KDM4ELMNA | |
| SCHEMBL9472796 | 0.82 | MAOA (0.35) | MAOAMAOBSMN1; SMN2HPGD | |
| SCHEMBL9347235 | 0.81 | ESR1 (0.43) | PPARGALDH1A1LMNAMAPTCYP3A4 | |
| SCHEMBL11934179 | 0.81 | TP53 (0.42) | PPARGPPARARAB9ASMN1; SMN2MAPT | |
| SCHEMBL14542685 | 0.81 | AGXT (0.43) | RAB9AALDH1A1MAOBSMN1; SMN2KDM4E | |
| SCHEMBL14524062 | 0.81 | CYP3A4 (0.35) | PPARGPPARASMN1; SMN2CYP3A4HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802135-B2 | Lysophosphatidic acid derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-10-31 | — | — | US | disclosed |
| US-11802135-B2 | Lysophosphatidic acid derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-10-31 | — | — | US | disclosed |
| US-11802135-B2 | Lysophosphatidic acid derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-10-31 | — | — | US | disclosed |
| US-20230146210-A1 | NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20230146210-A1 | NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20230146210-A1 | NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20160151322-A1 | METALLO-B-LACTAMASE INHIBITORS | MEIJI SEIKA KAISHA (JP) | 2016-06-02 | — | — | US | disclosed |
| US-9260375-B2 | Metallo-β-lactamase inhibitors | MEIJI SEIKA KAISHA, LTD. (JP) | 2016-02-16 | — | — | US | disclosed |
| US-8178579-B2 | Histone deacetylase inhibitors; anticancer agents; antiprotozoa agents | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-05-15 | — | — | US | disclosed |
| US-20120071457-A1 | METALLO-BETA-LACTAMASE INHIBITORS | CHIKAUCHI KEN (JP) | 2012-03-22 | — | — | US | disclosed |
| US-8093294-B2 | Bacterial infections; effective for recovering the activities of beta-lactam antibiotics; 2-ethyl-3-methylmaleic acid dimethyl ester; maleic acid derivatives and/or dihydrofuranyl derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2012-01-10 | — | — | US | disclosed |
| US-20080269245-A1 | Dioxanes and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2008-10-30 | — | — | US | disclosed |
| EP-1941873-A1 | METALLO-BETA-LACTAMASE INHIBITOR | MEIJI SEIKA KAISHA LTD. (JP) | 2008-07-09 | — | — | EP | disclosed |
| US-20080090825-A1 | Metallo-beta-lactamase inhibitors | MEIJI SEIKA KAISHA, LTD. (JP) | 2008-04-17 | — | — | US | disclosed |
| US-7244853-B2 | Dioxanes and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-07-17 | — | — | US | disclosed |
| US-20040072849-A1 | Dioxanes and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-04-15 | — | — | US | disclosed |
| US-20030187027-A1 | Dioxanes and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-10-02 | — | — | US | disclosed |
| WO-2002089782-A2 | DIOXANES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090825-A1 | Metallo-beta-lactamase inhibitors | ME1, MGAM, GAA | PPARG 1435/4885PPARA 1461/4885RAB9A 2261/4885 |
| US-11802135-B2 | Lysophosphatidic acid derivative | LPAR4, LPAR2, LPAR1 | PPARG 463/4885PPARA 219/4885RAB9A 2299/4885 |
| US-20030187027-A1 | Dioxanes and uses thereof | UTS2R, HDAC5, AMDHD2 | PPARG 3326/4885PPARA 4010/4885RAB9A 3054/4885 |
| US-20120071457-A1 | METALLO-BETA-LACTAMASE INHIBITORS | ME1, MGAM, GAA | PPARG 1435/4885PPARA 1461/4885RAB9A 2261/4885 |
| US-20040072849-A1 | Dioxanes and uses thereof | UTS2R, HDAC5, AMDHD2 | PPARG 3404/4885PPARA 4088/4885RAB9A 3141/4885 |
| US-20080269245-A1 | Dioxanes and uses thereof | UTS2R, MAN2B2, AMDHD2 | PPARG 3730/4885PPARA 4318/4885RAB9A 3487/4885 |
| US-20160151322-A1 | METALLO-B-LACTAMASE INHIBITORS | ME1, MGAM, MANBA | PPARG 1515/4885PPARA 1588/4885RAB9A 2123/4885 |
| US-20230146210-A1 | NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE | LPAR4, LPAR2, LPAR1 | PPARG 581/4885PPARA 333/4885RAB9A 2106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.